This article is sponsored by Inotiv. In this VIEWS article, Drug Discovery & Development spoke with Inotiv’s Matt Westfall, Senior Director for Proteomics, and Mike Heaven, Principal Scientist, to explore how sophisticated lipid nanoparticle (LNP) bioanalysis is revolutionizing RNA-based gene therapy. Matt Westfall heads Inotiv’s proteomics group in Nashville. A long-time industry scientist and biochemist…